reports
Freshpet, Inc. Reports Fourth Quarter and Full Year 2025 Financial Res...
Freshpet, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results Full Year 2025 Net Sales Growth of 13% and Achieves Positive Free Cash Flow Provides Full Year 2026 Outlook BEDMINSTER, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today reported financial results for its fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights Compared to Prior Year Period Net sales of $285.2 million, an increase of 8.6%.Gross margin of 43.3%, compared to the prior year period of 42.5%.Adjusted Gross ...
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026 SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology”; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in the Wells Fargo Executive Biotech Summit, TD Cowen 46th Annual Health Care Conference, and UBS Biotech Summit. The details of the meetings are as follows: Wells Fargo Executive Biotech Summit Format: One-o...
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Res...
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced plans to report its fourth quarter and full year 2025 financial results and a business update on Friday, February 27th, 2026 before market open. The company will host a teleconference in conjunction with its financial results pre...
Freshpet, Inc. Announces Inducement Grant Under NASDAQ Listing Rule 56...
Freshpet, Inc. Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) BEDMINSTER, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today announced that the Compensation and Human Capital Management Committee of its Board of Directors approved an equity award as an inducement material to John O’Connor’s acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). In connection with his previously announced appointment as Chief Financial Officer, Mr. O’Connor was granted, effective February 9, 2026,...
- Jonathan Moreland
PMT PENNYMAC MORTGAGE INVESTMENT TRUST
TCBI TEXAS CAPITAL BANCSHARES INC.
SXI STANDEX INTERNATIONAL CORPORATION
PAYX PAYCHEX INC.
NBTB NBT BANCORP INC.
MNRO MONRO INC
LXRX LEXICON PHARMACEUTICALS INC.
LMAT LEMAITRE VASCULAR INC.
HUN HUNTSMAN CORPORATION
GME GAMESTOP CORP. CLASS A
FFIN FIRST FINANCIAL BANKSHARES INC
CR CRANE CO.
GAM GENERAL AMERICAN INVESTORS CO. INC.
ENPH ENPHASE ENERGY INC.
PCF PUTNAM HIGH INCOME SECURITIES FUND
AGYS AGILYSYS INC.
TYIA JOHNSON CONTROLS INTERNATIONAL PLC
LW LAMB WESTON HOLDINGS INC.
HWKN HAWKINS INC.
WDFC WD-40 COMPANY
HYT BLACKROCK CORPORATE HIGH YIELD FUND VI
CVCO CAVCO INDUSTRIES INC.
CRVS CORVUS PHARMACEUTICALS
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
ABT ABBOTT LABORATORIES
MVBF MVB FINANCIAL CORP
THM INTERNATIONAL TOWER HILL MINES LTD
NWFL NORWOOD FINANCIAL CORP.
ZIVO ZIVO BIOSCIENCE
SONO INC.
ANIX SONOS
ETON ANIXA BIOSCIENCES
AMTB ETON PHARMACEUTICALS
JYNT AMERANT BANCORP (A)
ALLY THE JOINT
CMTV GMAC LLC
ALXO COMMUNITY BANCORP INC. VT
AZYO ALX ONCOLOGY HOLDINGS
LUMN AZIYO BIOLOGICS
BST LUMEN TECHNOLOGIES INC.
LSF BLACKROCK SCIENCE AND TECHNOLOGY TRUST
VANI LAIRD SUPERFOOD INC
BOF VIVANI MEDICAL INC
WS WI BRANCHOUT FOOD INC.
MXF WORTHINGTON STEEL
GDV THE MEXICO FUND
PMN INC.
IP THE GABELLI DIVIDEND & INCOME TRUST
CVM PROMIS NEUROSCIENCES INC.
FEAM INTER PHARMA PUBLIC COMPANY LIMITED
BDSX CEL-SCI CORPORATION
MIGI 5E ADVANCED MATERIALS INC.
BIODESIX INC
MAWSON INFRASTRUCTURE GROUP INC
- Jonathan Moreland
SXI STANDEX INTERNATIONAL CORPORATION
LXRX LEXICON PHARMACEUTICALS INC.
FFIN FIRST FINANCIAL BANKSHARES INC
PCF PUTNAM HIGH INCOME SECURITIES FUND
CVCO CAVCO INDUSTRIES INC.
RRBI RED RIVER BANCSHARES
ALXO ALX ONCOLOGY HOLDINGS
FRST PRIMIS FINANCIAL CORP
WRB W.R. BERKLEY CORPORATION
GAM GENERAL DE ALQUILER DE MAQUINARIA
FIG FIGMA INC.
FEAM 5E ADVANCED MATERIALS INC.
Freshpet Strengthens Leadership Team with Strategic Appointments Acros...
Freshpet Strengthens Leadership Team with Strategic Appointments Across Finance and Supply Chain Appoints John O’Connor as Chief Financial Officer Appoints Ana Lopez as Senior Vice President Supply ChainCompany Reaffirms Full Year 2025 Outlook BEDMINSTER, N.J, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today announced the appointment of John O’Connor as Chief Financial Officer, effective February 9, 2026, and Ana Lopez as Senior Vice President of Supply Chain, effective February 2, 2026. Mr. O’Connor succeeds Ivan Garcia, who has served ...
Freshpet, Inc. to Report Fourth Quarter and Full Year 2025 Results on ...
Freshpet, Inc. to Report Fourth Quarter and Full Year 2025 Results on Monday, February 23, 2026 BEDMINSTER, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Freshpet, Inc. (Nasdaq: FRPT) (“Freshpet” or the “Company”) today announced it will report results for the fourth quarter and full year ended December 31, 2025 on Monday, February 23, 2026 before market open. The Company will host a conference call with members of the executive management team to discuss these results with additional comments and details. The conference call is scheduled to begin at 8:00 a.m. ET on Monday, February 23, 2026. ...
ALX Oncology Announces Pricing of Underwritten Offering
ALX Oncology Announces Pricing of Underwritten Offering SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced the pricing of an underwritten offering of common stock and pre-funded warrants. ALX Oncology is selling 76,979,112 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 18,574,120 shares of common stock in the offeri...
New Data Demonstrate CD47 Expression Level Helps Predict Response to A...
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer - Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer – - Full data set submitted for presentation at an upcoming scientific conference - SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-st...
Peoples Financial Corporation Reports Results for The Fourth Quarter o...
Peoples Financial Corporation Reports Results for The Fourth Quarter of 2025 BILOXI, Miss., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Peoples Financial Corporation (the “Company”) (OTCQX Best Market: PFBX), parent of The Peoples Bank (the “Bank”), announced earnings for the fourth quarter ending December 31, 2025. Additionally, the board of directors of Peoples Financial Corporation announced that it has approved an extension of the Company’s current stock repurchase program, originally set to expire on December 31, 2025, with no expiration date. The program authorizes the repurchase of up to the...
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conf...
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive Officer Jason Lettmann and Chief Medical Officer Barbara Klencke will deliver a corporate presentation on Thursday, January 15, 2026, at 12:00 ...
ALX Oncology Advances Separate Clinical Trials Evaluating Investigatio...
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 - First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy in HER2-positive metastatic breast cancer; interim analysis anticipated Q3 2026 – - Third dose cohort initiated in Phase 1 trial of ALX 2004; study remains on track to provide initial safety data in 1H 2026 - SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Hold...
ALX Oncology Announces Positive Results from Ongoing Investigator-Spon...
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting - Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an approximate 50% historical CR rate for R2 alone - Data indicates combination of evorpacept plus R2 was well-tolerated and provides impressive anti-tumor activity i...
Moody's Ratings affirms New Mountain Finance Corp.'s Baa3 issuer ratin...
Moody's Ratings (Moody's) has affirmed New Mountain Finance Corporation's (NMFC) Baa3 long-term issuer and senior unsecured ratings, and (P)Baa3 senior unsecured shelf ratings. The outlook remains stable. RATINGS RATIONALE NMFC's Baa3 ratings reflect the strong franchise and established track re...
ALX Oncology to Present at Upcoming Investor Conferences
ALX Oncology to Present at Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in both the Jefferies Global Healthcare Conference in London and Piper Sandler 37th Annual Global Healthcare Conference in New York. The details of the meetings are as follows: Jefferies Global Healthc...
Freshpet, Inc. to Participate in the Morgan Stanley Global Consumer & ...
Freshpet, Inc. to Participate in the Morgan Stanley Global Consumer & Retail Conference BEDMINSTER, N.J., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today announced that members of the executive management team will participate in the Morgan Stanley Global Consumer & Retail Conference in New York, NY. The fireside chat will be on Tuesday, December 2, 2025 at 4:30 p.m. ET. A live webcast and replay will be available on the "Investors" section of the Company's website at About FreshpetFreshpet's mission is to elevate the way we feed our ...
- Jonathan Moreland
LNG CHENIERE ENERGY INC.
WM WASTE MANAGEMENT INC.
VRSK VERISK ANALYTICS INC
SLGN SILGAN HOLDINGS INC.
SFNC SIMMONS FIRST NATIONAL CORPORATION CLASS A
OHI OMEGA HEALTHCARE INVESTORS INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
NBTB NBT BANCORP INC.
MTDR MATADOR RESOURCES COMPANY
MNRO MONRO INC
JBLU JETBLUE AIRWAYS CORPORATION
GBCI GLACIER BANCORP INC.
FISV FISERV INC.
FFIN FIRST FINANCIAL BANKSHARES INC
DENN DENNY'S CORPORATION
CNS COHEN & STEERS INC.
AMT AMERICAN TOWER CORPORATION
ASA ASA
NEWT NEWTEK BUSINESS SERVICES INC.
NCBS NICOLET BANKSHARES INC
RLMD RELMADA THERAPEUTICS
URE UR-ENERGY
KMI KINDER MORGAN INC CLASS P
MSM MSC INDUSTRIAL DIRECT CO. INC. CLASS A
NSC NORFOLK SOUTHERN CORPORATION
AJG ARTHUR J. GALLAGHER & CO.
WINA WINMARK CORP.
FND FLOOR & DECOR HOLDINGS INC. CLASS A
BX THE BLACKSTONE GROUP L.P.
MBIN MERCHANTS BANCORP
OBNK ORIGIN BANCORP
OSPN ONESPAN
FUSB FIRST US BANCSHARES INC
AVO MISSION PRODUCE
UTZ UTZ BRANDS INC (A)
OPCH OPTION CARE HEALTH INC
INTA INTAPP INC
CLVT CLARIVATE PLC
NVCT NUVECTIS PHARMA INC
BPRN BANK OF PRINCETON
GTE GRAN TIERRA ENERGY INC.
NCDL NUVEEN CHURCHILL DIRECT LENDING CORP
GAM GENERAL DE ALQUILER DE MAQUINARIA
LAW CS DISCO INC
GF THE NEW GERMANY FUND
ASST INC.
ASSET ENTITIES INC.
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides...
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric cancer patients with high CD47 expression Phase 2 ASPEN-09-Breast Cancer trial remains on track for FPI in Q4 2025 and will evaluate evorpacept efficacy by CD47 expression levels Phase 1 trial for ALX2004, a novel EGFR-targeted ADC, is currently enrolling patients in the second dose cohort and on track to deliver initial safety data in 1H 2026 Cash runway expe...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.